Entera Bio Reports Third Quarter 2019 Financial Results and Provides Operating Update Enrollment Continues for Phase 2 study for oral PTH in Osteoporosis; Top-line 3-month Biomarker Data expected in mid 2020Presented Positive Results of a Phase 2 PK/PD study in Hypoparathyroidism...

Entera Bio to Announce Third Quarter 2019 Financial Results on Thursday, November 21, 2019 BOSTON and JERUSALEM, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), announced today that it will report financial results for the third quarter and nine months ended September...

Entera Bio Reports Positive Results from a Phase 2 PK/PD Study of Oral PTH (1-34) in Patients with Hypoparathyroidism Results of a Phase 2 PK/PD study of Oral PTH (1-34) in patients with hypoparathyroidism were presented at the American Society for Bone and Mineral Research Annual MeetingData suggest favorable...

Entera Bio to Present at the Ladenburg Thalmann 2019 Healthcare Conference JERUSALEM, Israel and BOSTON, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) announced today that Adam Gridley, CEO, and Dr. Phillip Schwartz, President of R&D, will present...

Entera Bio Reports Second Quarter 2019 Financial Results and Provides Operating Update Phase 2 study for oral PTH in osteoporosis was initiated in June 2019; Data expected in 2020Completed Part 2 of a Phase 2 PK/PD study in hypoparathyroidism patients. Results expected to be presented...